



Year: 2019

CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors

Fankhauser, Christian Daniel ; Roth, Lisa ; Grossmann, Nico Christian ; Kranzbühler, Benedikt ; Eberli, Daniel ; Sulser, Tullio ; Moch, Holger ; Bode, Peter-Karl ; Beyer, Joerg ; Hermanns, Thomas

Abstract: BACKGROUND To validate the utility of the chemokine ligand 12 (CXCL12) as prognostic marker in patients with localized and metastatic germ cell tumors (GCT). METHODS CXCL12 expression was analyzed on a tissue microarray consisting of 750 tissue cores of different histological tumor components, Germ cell neoplasia in situ (GCNIS) and adjacent normal tissue of 263 testicular cancer patients using a semi-quantitative score. The association between CXCL12 expression and recurrence-free survival (RFS) as well as overall survival (OS) was assessed using Kaplan-Meier curves with log-rank tests. RESULTS CXCL12 expression was absent in all seminomas but was found in 52 of 99 (52.5%) non-seminomas. Follow-up was available for 260 patients of which 36 (13.8%) recurred. In patients with stage 1 non-seminoma GCT, CXCL12 expression was not associated with higher risk of disease recurrence ($p = 0.270$). In contrast, post chemotherapy RFS of patients with metastatic non-seminoma and positive CXCL12 expression was significantly shorter compared to CXCL12 negative patients ($p = 0.003$). OS differences were not statistically different between patients with CXCL12 positive or negative tumors for either localized or metastatic disease. CONCLUSIONS CXCL12 is almost exclusively expressed in non-seminoma. Pure seminoma, GCNIS and adjacent normal testicular tissue are CXCL12 negative. Our analysis suggests that patients with metastatic disease and a CXCL12-positive non-seminoma are at higher risk for disease recurrence after first-line chemotherapy and might thus be candidates for more intensive treatment and/or closer follow-up.

DOI: <https://doi.org/10.1186/s12885-019-5961-1>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-174741>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at:

Fankhauser, Christian Daniel; Roth, Lisa; Grossmann, Nico Christian; Kranzbühler, Benedikt; Eberli, Daniel; Sulser, Tullio; Moch, Holger; Bode, Peter-Karl; Beyer, Joerg; Hermanns, Thomas (2019). CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors. *BMC Cancer*, 19:802.


DOI: <https://doi.org/10.1186/s12885-019-5961-1>

RESEARCH ARTICLE

Open Access



CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors

Christian Daniel Fankhauser^{1*†} , Lisa Roth^{1†}, Nico Christian Grossmann¹, Benedikt Kranzbühler¹, Daniel Eberli¹, Tullio Sulser¹, Holger Moch², Peter-Karl Bode², Joerg Beyer³ and Thomas Hermanns¹

Abstract

Background: To validate the utility of the chemokine ligand 12 (CXCL12) as prognostic marker in patients with localized and metastatic germ cell tumors (GCT).

Methods: CXCL12 expression was analyzed on a tissue microarray consisting of 750 tissue cores of different histological tumor components, Germ cell neoplasia in situ (GCNIS) and adjacent normal tissue of 263 testicular cancer patients using a semi-quantitative score. The association between CXCL12 expression and recurrence-free survival (RFS) as well as overall survival (OS) was assessed using Kaplan-Meier curves with log-rank tests.

Results: CXCL12 expression was absent in all seminomas but was found in 52 of 99 (52.5%) non-seminomas. Follow-up was available for 260 patients of which 36 (13.8%) recurred. In patients with stage 1 non-seminoma GCT, CXCL12 expression was not associated with higher risk of disease recurrence ($p = 0.270$). In contrast, post chemotherapy RFS of patients with metastatic non-seminoma and positive CXCL12 expression was significantly shorter compared to CXCL12 negative patients ($p = 0.003$). OS differences were not statistically different between patients with CXCL12 positive or negative tumors for either localized or metastatic disease.

Conclusions: CXCL12 is almost exclusively expressed in non-seminoma. Pure seminoma, GCNIS and adjacent normal testicular tissue are CXCL12 negative. Our analysis suggests that patients with metastatic disease and a CXCL12-positive non-seminoma are at higher risk for disease recurrence after first-line chemotherapy and might thus be candidates for more intensive treatment and/or closer follow-up.

Keywords: Testicular germ cell tumor, Biomarkers, tumor, Prognosis

Background

Testicular germ cell tumors (GCT) represent the most common solid neoplasm of men in their third and fourth decade [1]. Seventy percent of all patients are initially diagnosed with localized disease (i.e. stage I disease) [2]. If the cancer is limited to the testicle, the therapy involves surgical removal of the affected testicle, followed by a strict surveillance program including regular blood tests,

x-rays and computerized tomography [3, 4]. Despite the excellent prognosis of localized GCT, 15–30% of patients experience disease recurrence during surveillance [5]. An option to reduce the risk of recurrence is the administration of one cycle of adjuvant chemotherapy after orchiectomy, which reduces the risk of disease recurrence substantially [6]. Attempts have been made to stratify patients, who are at higher risk for disease recurrence based on different pathological characteristics (i.e. the size of the tumor and rete testis infiltration or the presence of lympho-vascular invasion and of embryonal carcinoma) [6–10]. However, the discovery of new

* Correspondence: Christian.fankhauser@usz.ch

†Christian Daniel Fankhauser and Lisa Roth contributed equally to this work.

¹Department of Urology, University Hospital, University of Zurich, Zurich, Switzerland

Full list of author information is available at the end of the article



markers that more reliably predict the risk of recurrence are of utmost importance.

Recently Gilbert et al. [11] were able to show that an increased expression of the chemokine ligand 12 (CXCL12) in the primary tumor was associated with a decreased relapse rate in patients with stage I non-seminoma. The authors concluded, that low CXCL12 expression might be a useful biomarker to identify patients who are at lower risk of recurrence and thus good candidates for active surveillance. However, those findings were somewhat surprising since CXCL12 is known as tumor promoting chemokine and high CXCL12 expression is actually associated with worse survival in most cancers [12]. The aims of our study were to externally validate the results of Gilbert et al. in patients with stage I disease and to extend the analysis to patients with metastatic GCT.

Methods

A consecutive series of patients with surgically resected testicular GCT between 2000 and 2014 was evaluated. Patients with bilateral testicular tumors, extra-gonadal primary or missing follow-up data were excluded from the analysis. Clinical characteristics (age, Body-Mass-Index (BMI), histology of the primary tumor, staging characteristics according to the tumor, nodes and metastases system (TNM) of the American Joint Committee on Cancer (AJCC) and to the International Germ Cell Cancer Collaborative Group (IGCCCG) and blood-based tumor markers (i.e. alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (b-hCG) and lactate dehydrogenase (LDH)) as well as follow-up information were extracted from the medical charts. The study was approved by the local ethics committee (KEK StV. 25–2008).

A tissue microarray (TMA) was constructed of formalin-fixed, paraffin-embedded tumor tissue of all included patients. If more than one tumor component was present in one patient all different GCT components were separately punched and included on the TMA. Tumors were classified by an experienced uropathologist (PKB) specialized in GCT pathology according to the 2016 WHO Classification [13]. Each tumor component was represented by two 0.6 mm diameter cores. The TMA was finally constructed with tissue cores of 263 GCT patients and included 99 Non-seminomas and 164 seminomas. The separately punched GCT components included: 422 seminomas, 172 embryonal carcinomas, 65 yolk sac tumors, 29 teratomas, 7 choriocarcinomas and 9 germ cell neoplasia in situ (GCNIS). Additionally, adjacent normal testicular tissue of 40 GCT patients was included.

Sections of 3 µm thickness of the TMA blocks were mounted on glass slides (SuperFrost Plus; Menzel,

Braunschweig, Germany), deparaffinized, rehydrated and stained with hematoxylin and eosin using standard histological techniques. CXCL12 immunohistochemistry was performed using the monoclonal CXCL12 antibody (Antibody 79018, 1:100; R&D Systems Minneapolis MN, USA). Peripheral neuronal tissue served as internal positive control for CXCL12 staining. The stained slides were digitalized and evaluated using imaging software (Spot browser, Alphelys, Plaisir, France). Two investigators (CDF, PKB) evaluated the CXCL12 staining of each spot on the TMA. A patient's tumor was classified as being positive if any of its components showed either moderate or strong CXCL12 expression and negative if CXCL12 expression was either absent or weak (Fig. 1).

Recurrence-free survival (RFS) and overall survival (OS) were calculated from time of diagnosis to first recurrence after initial management or death respectively. RFS and OS of patients with CXCL12 positive and negative tumors were compared using Kaplan-Meier curves and the log-rank test. Statistical analysis was performed using IBM SPSS Statistics (Version 21.0, Armonk, New York, USA: IBM Corp.). The results for continuous normally distributed variables are expressed as means \pm standard deviation (SD). Continuous non-normally distributed variables are presented as median and interquartile ranges (IQR). The results for categorical variables are presented as percentage. A *p*-value of < 0.05 was considered significant. All statistical tests were two-sided.

Results

The mean age at diagnosis was 26 years and patients were followed for a median of 64 months (Table 1). At initial diagnosis 190 of 263 patients (72%), were classified as stage I, 4 patients (2%) as stage IS, 35 patients (13%) as stage II and 34 patients (13%) as stage III. Of 132 patients with stage I seminoma, adjuvant chemotherapy with 1 cycle of carboplatin was administered to 70 patients (53%) and adjuvant radiotherapy to 6 patients (5%). Of 58 patients with stage I non-seminoma, adjuvant chemotherapy with 1 cycle of bleomycin, etoposide and cisplatin (BEP) was administered to 13 patients (22%). Of all 73 patients with metastases, 56 (76%) were classified as good risk, 13 (18%) as intermediate risk and 4 (6%) as poor risk according to the IGCCCG classification. All metastatic patients were treated with cisplatin based chemotherapy, most commonly with BEP (83%). Seven patients underwent retroperitoneal lymph node dissection due to post-chemotherapy residual masses.

CXCL12 expression was negative in normal tissue, GCNIS and seminoma tissue (Table 2). In patients with non-seminoma, CXCL12 expression was found in 52 patients (52.5%). Non-seminoma patients with CXCL12 expression in their primary tumor had significantly higher




Fig. 1 Examples of absent (a), weak (b) moderate (c) and strong (d) CXCL12 in seminoma (a), embryonal carcinoma (b & d) and yolk sac (c) tumor components

pre-orchietomy AFP values (118.7 $\mu\text{g/l}$ vs. 5.3 $\mu\text{g/l}$, $p < 0.001$) and b-HCG values (152.0 U/l vs. 8.2 U/l, $p < 0.001$) compared to CXCL12 negative patients (Fig. 2).

In patients with localized non-seminoma, CXCL12 expression was not significantly associated with time to

disease recurrence ($p = 0.27$) or time to death ($p = 0.17$) (Fig. 3). Also after controlling for adjuvant chemotherapy, no significant association between CXCL12 expression and time to recurrence was observed ($p = 0.4$). There was even a trend for a shorter time to recurrence in patients with high CXCL12 expression.

In patients with metastatic non-seminoma CXCL12 expression was not associated with worse IGCCCG risk groups ($p = 0.66$). In contrast, patients with metastatic non-seminoma and higher CXCL12 expression showed a significantly shorter time to disease recurrence ($p = 0.03$), whereas time to death was not significantly different ($p = 0.21$) compared to CXCL12 negative patients.

Discussion

In this study CXCL12 expression was observed in a large number of patients with non-seminoma but was absent in normal tissue, GCNIS or seminoma. We were not able to confirm the results by Gilbert and colleagues and even found a trend for a higher risk of disease recurrence in patients with high CXCL12 expression. Similarly to our results in stage I disease, CXCL12 expression was associated with a higher risk for disease recurrence in patients with metastatic non-seminoma after first line chemotherapy.

Table 1 Baselines characteristics

	N = 263
Age (years) (\pm SD)	26.4 (8.9)
Seminoma	164 (62%)
Non-Seminoma or mixed GCT	99 (38%)
Clinical Stage (AJCC)	
-Stadium I	190 (72%)
-Stadium IS	4 (2%)
-Stadium II	35 (13%)
-Stadium III	34 (13%)
IGCCCG risk groups	
-Good risk	56 (21%)
-Intermediate risk	13 (5%)
-Poor risk	4 (2%)

AJCC American Joint Committee on Cancer, BMI Body-Mass-Index (kg/cm²), IGCCCG International Germ Cell Cancer Collaborative Group, IQR Interquartile Range, SD Standard deviation, TNM tumor, nodes and metastases system of cancer staging

Table 2 CXCL12 expression on single core level and patient level

Single Cores	Semi-quantitative Score			
	negative	weak	moderate	strong
Seminoma (n = 422)	421 (99.8%)	0 (0.0%)	0 (0.0%)	1 (0.2%)
Embryonal Carcinoma (n = 172)	123 (70.7%)	0 (0.0%)	8 (4.6%)	43 (24.7%)
Teratoma (n = 29)	19 (59.3%)	0 (0.0%)	2 (6.3%)	11 (34.4%)
Yolk sack Tumor (n = 65)	5 (7.6%)	1 (1.5%)	11 (16.7%)	49 (74.2%)
Chorion Carcinoma (n = 7)	0 (0.0%)	0 (0.0%)	1 (14.3%)	6 (85.7%)
Patient Level	Dichotomized			
	Negative	Positive		
Non Seminoma or mixed GCT (n = 99)	47 (47.5%)	52 (52.5%)		
Pure Seminoma (n = 164)	164 (100%)	0 (0.0%)		
Normal tissue (n = 40)	40 (100%)	0 (0.0%)		
GCNIS (n = 9)	9 (100%)	0 (0.0%)		


Abbreviation: GCT germ cell tumor, GCNIS Germ cell neoplasia in situ


The chemokine CXCL12 has important physiological roles in embryonal development, vascular proliferation, hematopoiesis, and inflammation by interaction with different receptors such as the CXC chemokine receptor 4 (CXCR4) [14–16]. CXCL12/CXCR4 interaction is also known to be involved in tumor-promoting mechanisms which result in increased proliferation, invasion, adhesion, angiogenesis and decreased apoptosis [12]. High CXCL12 expression is known to be associated with worse survival in patients with different types of solid cancers [12].

The role of CXCL12 in GCT is controversial. In contrast to most solid cancers Gilbert et al. found that CXCL12 expression is a protective factor in patients with stage 1 non-seminoma [12]. However, in our analysis we were not able to confirm these findings of

Gilbert and our analyses suggest that CXCL12 might even be a risk factor and not a protective factor in stage 1 non-seminoma. Although both studies used the same antibody, our TMA based approach might have missed the heterogeneity of CXCL12 expression. As a conclusion of those contradictory results we currently discourage clinicians to use CXCL12 for clinical decision making until further studies clarify the role of CXCL12 in in stage 1 non-seminoma.

For metastatic GCTs, the IGCCCG classification is currently recommended to counsel patients with metastatic GCT regarding their risk of disease recurrence and survival and to guide treatment for these patients [17]. This classification is based on the histological subtypes (i.e. seminoma vs. non-seminoma), the location of the primary tumor and of the metastases and the tumor

**Fig. 2** Boxplots comparing AFP (a) and b-hCG (b) levels before orchiectomy between patients with negative and positive CXCL12 expression



markers levels. Our results suggest that CXCL12 expression in the primary tumor may improve risk stratification in patients with metastatic GCTs. Patients with metastatic disease and CXCL12 positive primary tumors may need more intense first-line chemotherapy and/or at least a closer post-chemotherapy follow-up.

The present analysis is limited by its retrospective design, single center approach and relatively small sample size. A further limitation of our study is that we were not able to perform a meaningful multivariate cox regression analysis due to the limited number of events. Additionally, multiple testing may lead to type I errors, which might overestimate the described associations between CXCL12 expression and oncologic outcomes. Thus, our analyses should rather be considered exploratory. A larger dataset including lymph vascular invasion status or IGCCCG classification is needed to reliably assess a potential independent prognostic impact

of CXCL12 expression in localised and metastatic disease respectively. Especially the planned IGCCCG update might be an opportunity to elucidate whether CXCL12 would ultimately possess the potential to predict oncologic outcomes besides the IGCCCG classification [18].

Conclusion

CXCL12 is exclusively expressed in non-seminoma and absent in seminoma, normal tissue or GCNIS. We were not able to show an association between CXCL12 and lower recurrence rates in stage I non-seminoma patients. However, positive CXCL12 expression was associated with shorter RFS after first-line chemotherapy in patients with metastatic GCT and thus might help to identify patients at a higher risk for disease recurrence.

Abbreviations

AFP: Alpha-fetoprotein; AJCC: American Joint Committee on Cancer; b-hCG: beta-human chorionic gonadotropin; CXCL12: Chemokine ligand 12; GCNIS: Germ cell neoplasia in situ; GCT: Testicular germ cell tumors; IGCCCG: International Germ Cell Cancer Collaborative Group; IQR: Interquartile ranges; LDH: Lactate dehydrogenase; OS: Overall survival; RFS: Recurrence-free survival; SD: Standard deviation; TMA: Tissue microarray; TNM: Tumor, nodes and metastases system

Authors' contributions

CDF, JB, TH conceived and designed the study, and wrote, edited and reviewed the manuscript. PB, CDF, LR, NCG, researched and analyzed data. CDF wrote the manuscript, BK, DE, TS, HM edited and reviewed the manuscript. All authors gave final approval for publication. CDF takes full responsibility for the work as a whole, including the study design, access to data and the decision to submit and publish the manuscript.

Funding

No funding

Availability of data and materials

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was approved by the local ethics committee Kanton Zurich and written informed consent was waived by the local ethics committee (KEK StV. 25–2008).

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Urology, University Hospital, University of Zurich, Zurich, Switzerland. ²Department of Pathology of Molecular Pathology, University Hospital, University of Zurich, Zurich, Switzerland. ³Department of Oncology, University Hospital, University of Bern, Bern, Switzerland.

Received: 2 April 2019 Accepted: 19 July 2019

Published online: 14 August 2019

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin*. 2017; 67(1):7–30.
2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. *CA Cancer J Clin*. 2014;64(4):252–71.
3. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, Nicolai N, Oldenburg J. Guidelines on testicular Cancer: 2015 update. *Eur Urol*. 2015.
4. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, et al. Testicular Cancer, version 2. 2015. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2015;13(6):772–99.
5. Mortensen MS, Lauritsen J, Kier MG, Bandak M, Appelt AL, Agerbaek M, Holm NV, Kempel MM, von der Maase H, Daugaard G. Late relapses in stage I testicular Cancer patients on surveillance. *Eur Urol*. 2016;70(2):365–71.
6. Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, Langberg C, Bremnes RM, Laurell A, Wijkstrom H, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. *J Clin Oncol*. 2009;27(13):2122–8.
7. Daugaard G, Gundgaard MG, Mortensen MS, Agerbaek M, Holm NV, Rorth M, von der Maase H, Christensen IJ, Lauritsen J. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. *J Clin Oncol*. 2014;32(34):3817–23.
8. Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, Powles T, Warde PR, Daneshmand S, Protheroe A, et al. Patterns

- of relapse in patients with clinical stage I testicular Cancer managed with active surveillance. *J Clin Oncol*. 2014.
9. Chung P, Daugaard G, Tyldesley S, Atenafu EG, Panzarella T, Kollmannsberger C, Warde P. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. *Cancer Med*. 2015;4(1):155–60.
10. Boormans JL, Mayor de Castro J, Marconi L, Yuan Y, Laguna Pes MP, Bokemeyer C, Nicolai N, Algaba F, Oldenburg J, Albers P. Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: a systematic review by the testicular Cancer guidelines panel. *Eur Urol*.
11. Gilbert DC, Al-Saadi R, Thway K, Chandler I, Berney D, Gabe R, Stenning SP, Sweet J, Huddart R, Shipley JM. Defining a new prognostic index for stage I Nonseminomatous germ cell tumors using CXCL12 expression and proportion of embryonal carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2016;22(5):1265–73.
12. Samarendra H, Jones K, Petrinic T, Silva MA, Reddy S, Soonawalla Z, Gordon-Weeks A. A meta-analysis of CXCL12 expression for cancer prognosis. *Br J Cancer*. 2017;117:124.
13. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs. Part A: Renal, Penile, and Testicular Tumours. *Eur Urol*. 2016;70(1):93–105.
14. Kim CH, Pelus LM, White JR, Broxmeyer HE. Differential chemotactic behavior of developing T cells in response to thymic chemokines. *Blood*. 1998;91(12):4434–43.
15. Peled A, Grabovsky V, Habler L, Sandbank J, Arenzana-Seisdedos F, Petit I, Ben-Hur H, Lapidot T, Alon R. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. *J Clin Invest*. 1999;104(9):1199–211.
16. Oberlin E, Amara A, Bachelier F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. *Nature*. 1996;382(6594):833–5.
17. International Germ Cell. Consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. International germ cell Cancer collaborative group. *J Clin Oncol*. 1997;15(2):594–603.
18. Collette L, Assele S. Update of the international prognostic classification for first line metastatic germ-cell cancers. An international initiative. European CanCer Organisation (ECCO) congress 2017, Abstract #2197 2017.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

